PL2753312T3 - Zastosowanie inhibitora aromatazy w leczeniu hipogonadyzmu i powiązanych chorób - Google Patents
Zastosowanie inhibitora aromatazy w leczeniu hipogonadyzmu i powiązanych choróbInfo
- Publication number
- PL2753312T3 PL2753312T3 PL12758965T PL12758965T PL2753312T3 PL 2753312 T3 PL2753312 T3 PL 2753312T3 PL 12758965 T PL12758965 T PL 12758965T PL 12758965 T PL12758965 T PL 12758965T PL 2753312 T3 PL2753312 T3 PL 2753312T3
- Authority
- PL
- Poland
- Prior art keywords
- hypogonadism
- treatment
- related diseases
- aromatase inhibitor
- aromatase
- Prior art date
Links
- 229940122815 Aromatase inhibitor Drugs 0.000 title 1
- 206010058359 Hypogonadism Diseases 0.000 title 1
- 239000003886 aromatase inhibitor Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532459P | 2011-09-08 | 2011-09-08 | |
| US201261638588P | 2012-04-26 | 2012-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2753312T3 true PL2753312T3 (pl) | 2017-06-30 |
Family
ID=46846026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12758965T PL2753312T3 (pl) | 2011-09-08 | 2012-09-06 | Zastosowanie inhibitora aromatazy w leczeniu hipogonadyzmu i powiązanych chorób |
| PL12758966T PL2753313T3 (pl) | 2011-09-08 | 2012-09-06 | Kompozycje farmaceutyczne zawierające inhibitor aromatazy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12758966T PL2753313T3 (pl) | 2011-09-08 | 2012-09-06 | Kompozycje farmaceutyczne zawierające inhibitor aromatazy |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9295668B2 (OSRAM) |
| EP (2) | EP2753312B1 (OSRAM) |
| JP (2) | JP6280501B2 (OSRAM) |
| KR (3) | KR20180030254A (OSRAM) |
| CN (2) | CN103796644B (OSRAM) |
| AR (1) | AR087790A1 (OSRAM) |
| AU (2) | AU2012304693B2 (OSRAM) |
| BR (2) | BR112014005434B1 (OSRAM) |
| CA (2) | CA2846884C (OSRAM) |
| CL (1) | CL2014000552A1 (OSRAM) |
| CY (2) | CY1118461T1 (OSRAM) |
| DK (2) | DK2753312T3 (OSRAM) |
| ES (2) | ES2613666T3 (OSRAM) |
| HR (2) | HRP20170002T1 (OSRAM) |
| HU (2) | HUE031478T2 (OSRAM) |
| IL (1) | IL231234A (OSRAM) |
| IN (1) | IN2014DN01619A (OSRAM) |
| LT (2) | LT2753312T (OSRAM) |
| MX (2) | MX343902B (OSRAM) |
| PE (1) | PE20141584A1 (OSRAM) |
| PH (1) | PH12014500435A1 (OSRAM) |
| PL (2) | PL2753312T3 (OSRAM) |
| PT (2) | PT2753312T (OSRAM) |
| RU (2) | RU2617510C2 (OSRAM) |
| SG (2) | SG2014012132A (OSRAM) |
| SI (2) | SI2753312T1 (OSRAM) |
| TN (1) | TN2014000059A1 (OSRAM) |
| TW (1) | TW201316987A (OSRAM) |
| UY (1) | UY34315A (OSRAM) |
| WO (2) | WO2013036562A1 (OSRAM) |
| ZA (1) | ZA201401040B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6280501B2 (ja) * | 2011-09-08 | 2018-02-14 | メレオ バイオファーマ ２ リミテッド | 性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用 |
| WO2015148549A1 (en) * | 2014-03-26 | 2015-10-01 | The Regents Of The University Of California | Ultrasensitive androgen receptor bioassay |
| SI3166596T1 (sl) * | 2014-07-07 | 2018-10-30 | Novartis Ag | Farmacevtske odmerne oblike |
| GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
| CN110520110A (zh) * | 2017-03-08 | 2019-11-29 | 阿瑞雅德制药公司 | 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂 |
| IL322969A (en) | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical therapy |
| USD894149S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| USD894148S1 (en) * | 2018-08-16 | 2020-08-25 | Alibaba Group Holding Limited | Information terminal for payment |
| JP7121999B2 (ja) * | 2019-09-26 | 2022-08-19 | 学校法人九州文化学園 | 男性性腺機能低下症治療剤 |
| US12552754B1 (en) | 2025-06-11 | 2026-02-17 | ReproNovo SA | Leflutrozole compositions of matter and processes for preparation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4749713A (en) | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| TW210334B (OSRAM) | 1990-12-12 | 1993-08-01 | Ciba Geigy Ag | |
| DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| AU2001271162A1 (en) * | 2000-07-05 | 2002-01-14 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition |
| CZ299735B6 (cs) * | 2001-04-17 | 2008-11-05 | Ares Trading S. A. | Farmaceutický prostredek |
| US7101573B2 (en) | 2001-09-28 | 2006-09-05 | Mcneil-Pcc, Inc. | Simethicone solid oral dosage form |
| EP1492515A1 (en) * | 2002-04-03 | 2005-01-05 | Jencap Research Ltd. | Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
| EP1937251A2 (en) | 2005-04-25 | 2008-07-02 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
| JPWO2009066712A1 (ja) | 2007-11-21 | 2011-04-07 | クラシエ製薬株式会社 | アロマターゼ阻害剤 |
| JP6280501B2 (ja) * | 2011-09-08 | 2018-02-14 | メレオ バイオファーマ ２ リミテッド | 性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用 |
-
2012
- 2012-09-06 JP JP2014529832A patent/JP6280501B2/ja active Active
- 2012-09-06 HU HUE12758965A patent/HUE031478T2/hu unknown
- 2012-09-06 MX MX2014002773A patent/MX343902B/es active IP Right Grant
- 2012-09-06 ES ES12758965.3T patent/ES2613666T3/es active Active
- 2012-09-06 SI SI201230850T patent/SI2753312T1/sl unknown
- 2012-09-06 US US14/342,810 patent/US9295668B2/en active Active
- 2012-09-06 LT LTEP12758965.3T patent/LT2753312T/lt unknown
- 2012-09-06 AR ARP120103283A patent/AR087790A1/es unknown
- 2012-09-06 CA CA2846884A patent/CA2846884C/en active Active
- 2012-09-06 DK DK12758965.3T patent/DK2753312T3/da active
- 2012-09-06 LT LTEP12758966.1T patent/LT2753313T/lt unknown
- 2012-09-06 HR HRP20170002TT patent/HRP20170002T1/hr unknown
- 2012-09-06 HU HUE12758966A patent/HUE031435T2/en unknown
- 2012-09-06 DK DK12758966.1T patent/DK2753313T3/en active
- 2012-09-06 WO PCT/US2012/053844 patent/WO2013036562A1/en not_active Ceased
- 2012-09-06 AU AU2012304693A patent/AU2012304693B2/en active Active
- 2012-09-06 WO PCT/US2012/053846 patent/WO2013036563A1/en not_active Ceased
- 2012-09-06 ES ES12758966.1T patent/ES2613667T3/es active Active
- 2012-09-06 SG SG2014012132A patent/SG2014012132A/en unknown
- 2012-09-06 KR KR1020187007058A patent/KR20180030254A/ko not_active Ceased
- 2012-09-06 PL PL12758965T patent/PL2753312T3/pl unknown
- 2012-09-06 KR KR1020147006170A patent/KR20140071358A/ko not_active Ceased
- 2012-09-06 EP EP12758965.3A patent/EP2753312B1/en active Active
- 2012-09-06 PT PT127589653T patent/PT2753312T/pt unknown
- 2012-09-06 BR BR112014005434-7A patent/BR112014005434B1/pt active IP Right Grant
- 2012-09-06 SI SI201230848A patent/SI2753313T1/sl unknown
- 2012-09-06 PT PT127589661T patent/PT2753313T/pt unknown
- 2012-09-06 RU RU2014113575A patent/RU2617510C2/ru active
- 2012-09-06 PE PE2014000325A patent/PE20141584A1/es not_active Application Discontinuation
- 2012-09-06 SG SG10201607503WA patent/SG10201607503WA/en unknown
- 2012-09-06 BR BR112014004879A patent/BR112014004879B1/pt active IP Right Grant
- 2012-09-06 PH PH1/2014/500435A patent/PH12014500435A1/en unknown
- 2012-09-06 PL PL12758966T patent/PL2753313T3/pl unknown
- 2012-09-06 CA CA2845929A patent/CA2845929C/en active Active
- 2012-09-06 EP EP12758966.1A patent/EP2753313B1/en active Active
- 2012-09-06 IN IN1619DEN2014 patent/IN2014DN01619A/en unknown
- 2012-09-06 AU AU2012304694A patent/AU2012304694B2/en active Active
- 2012-09-06 HR HRP20170003TT patent/HRP20170003T1/hr unknown
- 2012-09-06 US US14/342,813 patent/US9370505B2/en active Active
- 2012-09-06 MX MX2014002780A patent/MX360315B/es active IP Right Grant
- 2012-09-06 KR KR1020147006171A patent/KR101872561B1/ko active Active
- 2012-09-06 JP JP2014529833A patent/JP6051467B2/ja active Active
- 2012-09-06 CN CN201280043378.9A patent/CN103796644B/zh active Active
- 2012-09-06 RU RU2014113334A patent/RU2628808C2/ru active
- 2012-09-06 CN CN201280043614.7A patent/CN103781476B/zh active Active
- 2012-09-07 TW TW101132840A patent/TW201316987A/zh unknown
- 2012-09-10 UY UY0001034315A patent/UY34315A/es not_active Application Discontinuation
-
2014
- 2014-02-10 TN TNP2014000059A patent/TN2014000059A1/en unknown
- 2014-02-11 ZA ZA2014/01040A patent/ZA201401040B/en unknown
- 2014-02-27 IL IL231234A patent/IL231234A/en active IP Right Grant
- 2014-03-07 CL CL2014000552A patent/CL2014000552A1/es unknown
-
2016
- 2016-02-22 US US15/050,394 patent/US9750724B2/en active Active
- 2016-05-27 US US15/167,867 patent/US10064844B2/en active Active
-
2017
- 2017-01-18 CY CY20171100074T patent/CY1118461T1/el unknown
- 2017-01-24 CY CY20171100100T patent/CY1118499T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261768B (en) | Devices and methods for tissue treatment | |
| IL231234A0 (en) | Use of an aromatase inhibitor to treat hypogonadism and related diseases | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| ZA201209103B (en) | Vectors and sequences for the treatment of diseases | |
| SI2523661T1 (sl) | Nkcc inhibitorji za zdravljenje avtizma | |
| EP2627331A4 (en) | METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES | |
| SG10201507120TA (en) | Treatment of diseases | |
| ZA201403372B (en) | Therapeutic agents and uses thereof | |
| EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
| IL227972A0 (en) | Use of glycopyrrolate to treat tachycardia | |
| EP2707007A4 (en) | ANTIFUNGAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND NAILS | |
| SG11201500407XA (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| ZA201406146B (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| SMT201800604T1 (it) | Composti per il trattamento di obesita' e metodi di uso degli stessi | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| EP2814317A4 (en) | FUNGICIDAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND NAILS | |
| ZA201208389B (en) | Treatment of proliferative diseases | |
| EP2934501A4 (en) | USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES | |
| GB201114289D0 (en) | Flurbiprofen and related compounds for the treatment of skin diseases | |
| ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
| PL2574343T3 (pl) | Kompozycja do nanoszenia na skórę i zastosowanie tej kompozycji | |
| GB201113140D0 (en) | Prediction and treatment of cancer | |
| PT2456445E (pt) | Agente para o tratamento de condições da pele | |
| GB201117269D0 (en) | Peptoids for the phrophlyactic and therapeutic clearance of bacteria |